ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,567.19
      1.06%
      US Tech 100
      19,828.00
      0.95%
      Dow Jones
      39,375.87
      0.17%
      Brent Oil
      86.775
      0.00%
      Bitcoin
      58,218.88
      -0.14%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Lexicon Pharmaceuticals Inc (LXRX)

      7. Lexicon Pharmaceuticals Inc (LXRX) News

      LXRX

      Lexicon Pharmaceuticals (LXRX)

      Lexicon Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:LXRX
      DateTimeSourceHeadlineSymbolCompany
      10/11/20234:02PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
      10/11/20234:01PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
      10/11/20239:00AMGlobeNewswire Inc.Data Demonstrating Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National MeetingNASDAQ:LXRXLexicon Pharmaceuticals Inc
      10/09/20234:01PMGlobeNewswire Inc.INPEFA® (Sotagliflozin) Receives Preferred Formulary Status With Express Scripts For Medicare PatientsNASDAQ:LXRXLexicon Pharmaceuticals Inc
      10/09/20238:00AMGlobeNewswire Inc.Tom Garner Joins Lexicon as Senior Vice President and Chief Commercial OfficerNASDAQ:LXRXLexicon Pharmaceuticals Inc
      09/28/20239:00AMGlobeNewswire Inc.Lexicon to Present Post Hoc Analysis of Scored Clinical Trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023NASDAQ:LXRXLexicon Pharmaceuticals Inc
      09/26/20239:00AMGlobeNewswire Inc.Lexicon to Present Study Results Relating to Sotagliflozin and LX9211 at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      09/14/20235:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
      09/07/20234:30PMGlobeNewswire Inc.Lexicon Pharmaceuticals to Participate in the H.C. Wainwright & Co. 25th Annual Global Investment ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
      09/07/20239:00AMGlobeNewswire Inc.Lexicon Announces Series of Presentations Relating to LX9211, Its Investigational Drug for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      08/21/20239:00AMGlobeNewswire Inc.Lexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023NASDAQ:LXRXLexicon Pharmaceuticals Inc
      08/08/20239:00AMGlobeNewswire Inc.Published Analysis of Sotagliflozin (INPEFA(TM)) Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart FailureNASDAQ:LXRXLexicon Pharmaceuticals Inc
      08/07/20234:13PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
      08/04/20237:09AMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LXRXLexicon Pharmaceuticals Inc
      08/04/20237:07AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LXRXLexicon Pharmaceuticals Inc
      08/03/20234:08PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LXRXLexicon Pharmaceuticals Inc
      08/03/20234:01PMGlobeNewswire Inc.Lexicon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:LXRXLexicon Pharmaceuticals Inc
      07/31/20234:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LXRXLexicon Pharmaceuticals Inc
      07/31/20238:14AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
      07/31/20238:13AMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
      07/28/20234:01PMGlobeNewswire Inc.Lexicon Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 3, 2023NASDAQ:LXRXLexicon Pharmaceuticals Inc
      07/28/20238:00AMGlobeNewswire Inc.Lexicon Elects Diane E. Sullivan to Board of DirectorsNASDAQ:LXRXLexicon Pharmaceuticals Inc
      07/24/20234:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LXRXLexicon Pharmaceuticals Inc
      07/12/20234:34PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
      06/29/20234:14PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      06/29/20234:13PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
      06/28/20234:22PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      06/28/20234:20PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LXRXLexicon Pharmaceuticals Inc
      06/27/20234:23PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      06/26/20234:05PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:LXRX